Associated Papers
The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele-Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization.
Shilbayeh SAR et al.
Pharmacology Research & Perspectives, 2025
SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.
Moustafa HAM et al.
Functional & Integrative Genomics, 2025
Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.
Ebaid NF et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2024
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
Lubieniecka JM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2013
Pharmacogenetics of genes across the doxorubicin pathway.
Jamieson D et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.
Gonzalez-Covarrubias V et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S et al.
Cancer Science, 2008
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L et al.
Pharmacogenetics and Genomics, 2008